Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toni Giorgino

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The EMBO Journal|October 31, 2022
Maternal immune activation leads to defective brain-blood vessels and intracerebral hemorrhages in male offspringMarco Rasile, Eliana Lauranzano, Elisa Faggiani, et al.
The EMBO Journal|May 15, 2023
Maternal immune activation leads to defective brain blood vessels and intracerebral hemorrhages in male offspringMarco Rasile, Eliana Lauranzano, Elisa Faggiani, et al.
Blood|March 19, 2015
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisNicolaus Kröger, Toni Giorgino, Bart L Scott, et al.
Frontiers in Cellular and Infection Microbiology|December 10, 2024
The antipsychotic drug lurasidone inhibits coronaviruses by affecting multiple targetsSara Baroni, Tea Carletti, Manuela Donalisio, et al.
Computational and Structural Biotechnology Journal|December 23, 2021
A novel hotspot of gelsolin instability triggers an alternative mechanism of amyloid aggregationMichela Bollati, Luisa Diomede, Toni Giorgino, et al.
Leukemia Research|May 8, 2018
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemiaBarbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Blood Cancer Journal|October 7, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC projectDaniela Barraco, Barbara Mora, Paola Guglielmelli, et al.
Blood Advances|November 8, 2019
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patientsMargherita Maffioli, Toni Giorgino, Barbara Mora, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The EMBO Journal|October 31, 2022
Maternal immune activation leads to defective brain-blood vessels and intracerebral hemorrhages in male offspringMarco Rasile, Eliana Lauranzano, Elisa Faggiani, et al.
The EMBO Journal|May 15, 2023
Maternal immune activation leads to defective brain blood vessels and intracerebral hemorrhages in male offspringMarco Rasile, Eliana Lauranzano, Elisa Faggiani, et al.
Blood|March 19, 2015
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosisNicolaus Kröger, Toni Giorgino, Bart L Scott, et al.
Frontiers in Cellular and Infection Microbiology|December 10, 2024
The antipsychotic drug lurasidone inhibits coronaviruses by affecting multiple targetsSara Baroni, Tea Carletti, Manuela Donalisio, et al.
Computational and Structural Biotechnology Journal|December 23, 2021
A novel hotspot of gelsolin instability triggers an alternative mechanism of amyloid aggregationMichela Bollati, Luisa Diomede, Toni Giorgino, et al.
Leukemia Research|May 8, 2018
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemiaBarbara Mora, Toni Giorgino, Paola Guglielmelli, et al.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Cancer Medicine|June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patientsBarbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
Blood Cancer Journal|October 7, 2018
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC projectDaniela Barraco, Barbara Mora, Paola Guglielmelli, et al.
Blood Advances|November 8, 2019
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patientsMargherita Maffioli, Toni Giorgino, Barbara Mora, et al.
Pageof 6